Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine

Sibling Oocyte Study of Medium for IVF/ICSI With no Human Serum Albumine

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00541892

Enrollment

Registered

2007-10-10

Start date

2007-09-30

Completion date

2014-01-31

Last updated

2015-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, In Vitro Fertilization

Keywords

Cell Culture Techniques

Brief summary

The purpose of this study is to determine if a new medium with no human serum albumine added is as good as the media conventionally used for IVF/ICSI.

Detailed description

Cells attained in IVF/ICSI procedures are kept in a medium that nurture the cells. Until now all such media have contained human serum albumine. The purpose of this study is to determine if a new medium with no human serum albumine added is as good as the media conventionally used for IVF/ICSI.

Interventions

OTHERMedium with no human serum albumine added

See above

OTHERConventional medium

See above

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 38 Years

Healthy volunteers

Inclusion criteria

* Couples seeking IVF/ICSI. * Female under 38 years of age. * No more than two previous IVF/ICSI treatments without pregnancy. * Regular menstruation periods. * No endocrine disease that requires treatment in the female. * BMI below 30 in the female. * At least 8 mature follicles upon monitoring or 6 MII oocytes upon ICSI. * Written informed consent.

Exclusion criteria

* Low responders to FSH. * Females in danger of developing OHSS. * Sperm sample below ICSI-quality.

Design outcomes

Primary

Measure	Time frame
Fertilization	24 hours
Cleavage	48 hours
Embryo score	48 hours
Embryos used	48 hours

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026